These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 25770144

  • 1. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C, Semeraro F, dell'Omo R, Romano MR, Russo A, Aceto F, Mastropasqua R, Porcellini A.
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [Abstract] [Full Text] [Related]

  • 2. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 3. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
    Wang JW, Zhou MW, Zhang X, Huang WB, Gao XB, Wang W, Chen S, Zhang XY, Ding XY, Jonas JB.
    Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
    [Abstract] [Full Text] [Related]

  • 4. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK, Moon HJ.
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [Abstract] [Full Text] [Related]

  • 5. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
    Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS.
    Am J Ophthalmol; 2006 Mar; 141(3):456-62. PubMed ID: 16490490
    [Abstract] [Full Text] [Related]

  • 6. Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization.
    Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M.
    Acta Ophthalmol; 2011 Aug; 89(5):459-62. PubMed ID: 20102348
    [Abstract] [Full Text] [Related]

  • 7. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
    Park SP, Ahn JK.
    Clin Exp Ophthalmol; 2009 Jul; 37(5):490-5. PubMed ID: 19624346
    [Abstract] [Full Text] [Related]

  • 8. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R, Cassetta M, dell'Omo E, di Salvatore A, Hughes JM, Aceto F, Porcellini A, Costagliola C.
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [Abstract] [Full Text] [Related]

  • 9. Associations of inflammatory cytokines with choroidal neovascularization in highly myopic eyes.
    Yamamoto Y, Miyazaki D, Sasaki S, Miyake K, Kaneda S, Ikeda Y, Baba T, Yamasaki A, Noguchi Y, Inoue Y.
    Retina; 2015 Feb; 35(2):344-50. PubMed ID: 25289657
    [Abstract] [Full Text] [Related]

  • 10. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K, Uematsu S, Hara C, Wakabayashi T, Fukushima Y, Sato S, Ikuno Y, Nishida K.
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F.
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [Abstract] [Full Text] [Related]

  • 12. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Retina; 2010 Sep; 30(7):1034-8. PubMed ID: 20616682
    [Abstract] [Full Text] [Related]

  • 13. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S.
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [Abstract] [Full Text] [Related]

  • 14. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ, Park KH, Woo SJ.
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study.
    Pasyechnikova NV, Naumenko VO, Korol AR, Zadorozhnyy OS, Kustryn TB, Henrich PB.
    Ophthalmologica; 2015 Sep; 233(1):2-7. PubMed ID: 25501802
    [Abstract] [Full Text] [Related]

  • 16. Anti-VEGF therapy in myopic choroidal neovascularization: long-term results.
    Freitas-da-Costa P, Pinheiro-Costa J, Carvalho B, Falcão M, Brandão E, Falcão-Reis F, Carneiro Â.
    Ophthalmologica; 2014 Sep; 232(1):57-63. PubMed ID: 24852069
    [Abstract] [Full Text] [Related]

  • 17. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
    Cohen SY, Nghiem-Buffet S, Grenet T, Dubois L, Ayrault S, Fajnkuchen F, Delahaye-Mazza C, Quentel G, Tadayoni R.
    Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
    [Abstract] [Full Text] [Related]

  • 18. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.
    Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M.
    Jpn J Ophthalmol; 2009 May; 53(3):243-8. PubMed ID: 19484443
    [Abstract] [Full Text] [Related]

  • 19. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.
    Cohen SY.
    Retina; 2009 Sep; 29(8):1062-6. PubMed ID: 19734760
    [Abstract] [Full Text] [Related]

  • 20. Low levels of pigment epithelium-derived factor in highly myopic eyes with chorioretinal atrophy.
    Ogata N, Imaizumi M, Miyashiro M, Arichi M, Matsuoka M, Ando A, Matsumura M.
    Am J Ophthalmol; 2005 Nov; 140(5):937-9. PubMed ID: 16310484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.